U.S. Markets closed
  • S&P Futures

    4,217.75
    +4.00 (+0.09%)
     
  • Dow Futures

    33,799.00
    +38.00 (+0.11%)
     
  • Nasdaq Futures

    14,135.50
    +5.50 (+0.04%)
     
  • Russell 2000 Futures

    2,283.00
    +2.10 (+0.09%)
     
  • Crude Oil

    73.48
    -0.18 (-0.24%)
     
  • Gold

    1,784.10
    +1.20 (+0.07%)
     
  • Silver

    25.99
    -0.03 (-0.13%)
     
  • EUR/USD

    1.1915
    -0.0010 (-0.0834%)
     
  • 10-Yr Bond

    1.4840
    +0.0340 (+2.34%)
     
  • Vix

    17.89
    -2.81 (-13.57%)
     
  • GBP/USD

    1.3923
    -0.0010 (-0.0696%)
     
  • USD/JPY

    110.3280
    +0.0300 (+0.0272%)
     
  • BTC-USD

    31,622.38
    -4,018.77 (-11.28%)
     
  • CMC Crypto 200

    759.92
    -90.42 (-10.63%)
     
  • FTSE 100

    7,062.29
    +44.82 (+0.64%)
     
  • Nikkei 225

    28,010.93
    -953.17 (-3.29%)
     

Aurinia Pharma's Stock Gains After Lupkynis Data From Late-Stage Lupus Nephritis Study Published In Lancet

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has announced that The Lancet published its Phase 3 AURORA 1 study evaluating Lupkynis (voclosporin) in adults with lupus nephritis (LN).

  • The study results demonstrated that Lupkynis combined with mycophenolate mofetil (MMF) and low-dose corticosteroids led to statistically superior complete renal response rates at 52 weeks compared to treatment with MMF and low-dose corticosteroids alone, with a comparable safety profile.

  • In January this year, the FDA had approved Lupkynis combined with a background immunosuppressive therapy regimen for LN.

  • AURORA 1 met its primary endpoint, achieving statistically superior complete renal response rates of 41% in the Lupkynis group versus 23% in the control group.

  • Lupkynis also achieved statistical significance in all pre-specified hierarchical secondary endpoints, including improved time to 50% reduction from baseline in urine protein creatinine ratio (UPCR) or and time to UPCR <0.5 mg/mg compared to control.

  • Lupkynis was well tolerated with no unexpected safety signals.

  • Additionally, the Lupkynis group showed no notable decrease at Week 52 in mean eGFR or increase in mean blood pressure, lipids, or glucose, which are common adverse events associated with traditional calcineurin inhibitors.

  • Price Action: AUPH share is up 4.3% at $10.59 during the premarket session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.